While employer-sponsored health benefits are not likely to disappear, changes that shift financial risk to employees are certain.
According to Deloitte, U.S. employers are concerned about continued rising healthcare costs; however, they are unaware of solutions that could improve the safety and quality of care, and simultaneously reduce cost. While employer-sponsored health benefits are not likely to disappear, changes that shift financial risk to employees are certain, according to the company’s survey.
The survey of employers with 50+ workers offering health benefits explores employers’ opinions about the U.S. healthcare system, the Patient Protection and Affordable Care Act (PPACA), and anticipated strategies for employee health benefits coverage and cost containment.
Survey results also revealed:
35% of employers surveyed grade system performance as an “A” or a “B.” Employers hold favorable views about the system’s clinical capabilities and medical innovation, but unfavorable views center on its wastefulness and high costs.
Employers believe that they have a “good” understanding of the PPACA. Familiarity with the individual mandate is the highest (72%). Most employers say their company is “not well prepared” to implement the 2014 provisions of the ACA.
30% think the PPACA is “a good start,” 59% “a step in the wrong direction.”
To manage healthcare costs, increased cost sharing with employees is considered the optimal strategy.
When considering healthcare related strategies to reduce the deficit, employers support reforms in medical liability, Medicare and Medicaid, and repeal/delay of the PPACA. Across-the-board cuts in government spending are considered a higher priority than changes to the healthcare system.
Go back to the Managed Healthcare Executive eNews newsletter.
FDA Updates for Week of April 29, 2024: Full Approval for Tivdak
May 4th 2024The FDA made several approvals this week, including converting Tivdak’s accelerated approval to full approval for cervical cancer and approvals for a high-concentration formulation of Cyltezo, Xolremdi for an ultra rare immune disorder and Libervant Film for epilepsy in young children.
Read More
Older Adults' Concerns Highlight Healthcare Cost and Access Challenges
May 3rd 2024The University of Michigan National Poll on Healthy Aging recently conducted the survey focusing on the concerns of adults aged 50 and above regarding various health-related issues in their communities.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen